Clinical Trials
4 trialsNCT06469944 2026-05-26
MK-3475-06C
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06780111 2026-03-31
MK-3475-06E
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06428409 2026-01-22
MK-9999-02A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT05319639 2025-02-27
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
Fujian Cancer Hospital
Phase 1/2 Recruiting